Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun;43 Suppl 2(Suppl 2):e70080.
doi: 10.1002/hon.70080.

Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Update on Biology and Treatment

Peter Borchmann  1   2 , Dennis A Eichenauer  1   2 , Gerard Frigola  3   4 , Elias Campo  3   4
Affiliations
Review

Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Update on Biology and Treatment

Peter Borchmann et al. Hematol Oncol. 2025 Jun.

Abstract

Nodular lymphocyte-predominant B-cell/Hodgkin lymphoma (NLPB/HL) accounts for roughly 5% of all Hodgkin lymphoma (HL) cases. In contrast to classic HL (cHL), the malignant cells in NLPB/HL lack CD30 expression but maintain a complete phenotype of mature B-cells including CD20 and IgG, but occasionally show IgD expression. The tumor cells are known as lymphocyte-predominant (LP) cells and grow in a T-cell and histiocyte rich microenvironment against a background of follicular dendritic cells. Transformation to large B cell lymphoma may occur and requires excisional lymph node biopsies. Most patients with NLPB/HL present in early stages. The disease usually has an indolent clinical course. Approaches applied in cHL result in very good outcomes with only limited excess mortality in comparison with the general population. Activity has also been demonstrated for rituximab-containing regimens commonly used in indolent B-cell non-Hodgkin lymphoma. The present article reviews pathological characteristics, treatment options and tools that might improve risk stratification in NLPB/HL.

Keywords: Hodgkin lymphoma; T‐cell and histiocyte reach large B‐cell lymphoma; immuno‐architectural patterns; lymphoma transformation; nodular lymphocyte‐predominant B‐cell/Hodgkin lymphoma.

PubMed Disclaimer

Conflict of interest statement

E.C. has been has received honoraria from Janssen, EUSA Pharma, Roche and ThermoFisher for speaking at educational activities and research funding from AstraZeneca and is an inventor on 2 patents filed by the National Institutes of Health, National Cancer Institute: “Methods for selecting and treating lymphoma types,” licensed to NanoString Technologies, and “Evaluation of mantle cell lymphoma and methods related thereof.” E.C. has licensed the use of the protected IgCaller algorithm for Diagnóstica Longwood and Sohia genomics.

References

    1. Campo E., Jaffe E. S., Cook J. R., et al., “The International Consensus Classification of Mature Lymphoid Neoplasms: A Report From the Clinical Advisory Committee,” Blood 140, no. 11 (2022): 1229–1253, 10.1182/blood.2022015851. - DOI - PMC - PubMed
    1. Armitage J. O., Gale R. P., and Jaffe E. S., “Lymphoma Nomenclature – What's in a Name?,” British Journal of Haematology 197, no. 5 (2022): 539–543, 10.1111/bjh.18063. - DOI - PMC - PubMed
    1. Nam‐Cha S. H., Roncador G., Sanchez‐Verde L., et al., “PD‐1, a Follicular T‐Cell Marker Useful for Recognizing Nodular Lymphocyte‐Predominant Hodgkin Lymphoma,” American Journal of Surgical Pathology 32, no. 8 (2008): 1252–1257, 10.1097/pas.0b013e318165b0d6. - DOI - PubMed
    1. Bein J., Thurner L., Hansmann M. L., and Hartmann S., “Lymphocyte Predominant Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma Interact With Rosetting T Cells in an Immunological Synapse,” American Journal of Hematology 95, no. 12 (2020): 1495–1502, 10.1002/ajh.25972. - DOI - PubMed
    1. Venkataraman G., Raffeld M., Pittaluga S., and Jaffe E. S., “CD15‐Expressing Nodular Lymphocyte‐Predominant Hodgkin Lymphoma,” Histopathology 58, no. 5 (2011): 803–805, 10.1111/j.1365-2559.2011.03829.x. - DOI - PMC - PubMed